Veeda Clinical Research Limited
₹428▼4.46%(20.00)
About the company
Veeda Clinical Research Limited is one of India's leading independent Contract Research Organizations (CROs), providing comprehensive clinical research services to pharmaceutical, biotechnology, and healthcare companies worldwide. Established in 2004, the company has built a strong reputation for delivering high-quality, science-driven research solutions that support the development of safe and effective medicines while meeting global regulatory standards.
Veeda offers a full range of end-to-end clinical research services, including pre-clinical support, early-phase and late-phase clinical trials, bioanalytical services, and clinical data management. Its integrated business model enables clients to efficiently manage the drug development process from research through regulatory approval. With a strong focus on quality, regulatory compliance, innovation, and timely project execution, Veeda Clinical Research Limited continues to play an important role in advancing clinical research and helping bring new healthcare therapies to patients across the globe.
Fundamentals
Valuation
Registry
| Metric | Value |
|---|---|
| PAN number | AACCC3633Q |
| ISIN number | INE01HQ01026 |
| CIN | U73100GJ2004PLC044023 |
Figures in cr ·
Financials
| P&L Statement | 2025Latest | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 610 | 388 | 409 | 288 | 196 | 151 |
| EBITDA | 125 | 53 | 103 | 62 | 67 | 20 |
| OPM | 20.49 | 13.66 | 25.18 | 21.53 | 34.18 | 13.25 |
| PBT | -66 | 3.3 | 59 | 65 | 85 | 0.89 |
| PAT | -67 | -0.3 | 42 | 50 | 63 | -0.01 |
| EPS | -10.19 | -0.04 | 8 | 9.46 | 17.6 | 0 |
Shareholding Pattern
| Holder | Percentage |
|---|---|
| Basil Private Limited | 33.83% |
| Bondway Investment Inc. | 19.20% |
| Others | 46.97% |
Leadership
Frequently asked questions
Common questions on Veeda Clinical Research Limited—tap a row to read the answer.
Q.1What does Veeda Clinical Research Limited do?
Veeda Clinical Research Limited is a leading Indian Contract Research Organization (CRO) that provides end-to-end clinical research services to pharmaceutical, biotechnology, and healthcare companies. Its services include early and late-phase clinical trials, bioanalytical testing, clinical data management, and regulatory support to help bring new medicines to market efficiently
Q.2What should investors consider before investing in Veeda Clinical Research Limited?
Before investing, it is important to evaluate the company's financial performance, research capabilities, client base, regulatory compliance, management team, growth strategy, industry outlook, and valuation. Reviewing these factors can help investors make a well-informed investment decision.
Q.3What are the risks of investing in Veeda Clinical Research Limited unlisted shares?
Like any unlisted investment, Veeda Clinical Research Limited shares carry certain risks, including limited liquidity, price volatility, lower public disclosure, and uncertainty regarding future listing plans. Investors should carefully assess these risks and align them with their investment goals.
Q.4Does Veeda Clinical Research Limited have any IPO plans?
As of now, there is no officially confirmed IPO date for Veeda Clinical Research Limited. Any future plans for a public listing are expected to be announced through official company communications and applicable regulatory filings.
Q.5. How is the price of Veeda Clinical Research Limited unlisted shares determined?
The price of Veeda Clinical Research Limited unlisted shares depends on several factors, including the company's financial performance, business growth, client portfolio, investor demand, industry trends, market sentiment, and recent transactions in the unlisted shares market.
Unlisted Trending shares
High-demand unlisted opportunities currently available for trade.
MARKET INSIGHTS & UPDATES
Read the latest updates, investment ideas, and market insights designed to help investors better understand unlisted and pre-IPO opportunities.

Top 10 Unlisted Shares in India in 2026: Companies, Fundamentals & What Investors Should Know
Explore 10 unlisted shares in India in 2026, including MSEI, Garuda Aerospace, OYO, Goodluck Defence, 63SATS, NCDEX, API Holdings and more.

Unlisted Share Price List India — Buy and sell Pre-IPO Shares
Unlisted shares pertain to equity shares which are not listed on recognized stock exchanges. This guide explains the mechanics of unlisted shares, the process by which an investor can purchase them, the method of valuation and red flags which should be noted by an investor prior to buying unlisted shares. The article also highlights the differences between listed, unlisted, and pre-IPO shares while discussing the risks such as low liquidity, valuation, business, and IPO risk. The article provides a checklist and frequently asked questions to understand the nuances of unlisted shares.

MSEI, Zepto and Other Pre-IPO Shares Move: 2026 Performance
MSEI surged over 124% while Zepto declined nearly 48% in 2026. Explore how other pre-IPO and unlisted shares performed and what the latest market trends mean for investors.

Sagar Defence Unlisted Share: Price, Financials & Why Investors Are Watching This Defence-Tech Stock
Sagar Defence Engineering's unlisted shares are drawing attention as India's defence-tech push gains momentum. Here's a look at the company, its FY26 numbers, and what to know before investing.

API Holdings & MSEI Unlisted Shares Surge: What’s Driving the Rally?
API Holdings and MSEI unlisted shares are witnessing sharp price movements, attracting fresh investor attention. Discover what is driving the rally, the latest trends and key factors to consider before investing.

NSE IPO Price Band vs NSE Unlisted Share Price — What Is the Difference?
The upcoming NSE IPO has created strong interest around the difference between the -NSE IPO price band and NSE unlisted share price. Recent reports indicate a possible IPO price range of ₹1,700–₹1,785, while NSE unlisted shares were around ₹2,045 on 9 September 2026. This blog explains why these prices can differ and covers NSE’s latest financial performance, valuation, IPO structure, lock-in period, business strengths and key risks investors should understand before evaluating NSE shares.
